AKROEarnings•globenewswire•
Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Sentiment:Neutral (40)
Summary
Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 8, 2025 by globenewswire